Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research7/2/2026Positive
ABSI
Absci CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.92B
P/E Ratio
—
EPS
$-0.80
Beta
2.33
52W High
$12.05
52W Low
$2.24
50-Day MA
$6.84
200-Day MA
$4.15
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Absci Corp
Absci Corp (ABSI) is an innovative biotechnology firm leveraging an advanced AI-driven platform to transform drug discovery. By enabling the swift generation of high-quality proteins and therapeutic candidates, the company accelerates development timelines and reduces costs, positioning itself as a vital player in the biopharmaceutical landscape. Absci's strategic collaborations with various partners highlight its dedication to creating next-generation therapies, while its expanding pipeline of proprietary programs underscores its potential to drive significant advancements in healthcare and tackle pressing medical challenges.
Fundamentals
| Revenue (TTM) | $1.84M |
| Gross Profit (TTM) | $-81.79M |
| EBITDA | $-116.44M |
| Operating Margin | -14347.00% |
| Return on Equity | -63.90% |
| Return on Assets | -37.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $1.11 |
| Price-to-Book | 11.42 |
| Price-to-Sales (TTM) | 1045.37 |
| EV/Revenue | 1003.3 |
| EV/EBITDA | -0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -81.80% |
| Shares Outstanding | $169.40M |
| Float | $148.83M |
| % Insiders | 12.03% |
| % Institutions | 72.96% |
Historical Volatility
HV 10-Day
157.99%
HV 20-Day
135.91%
HV 30-Day
145.33%
HV 60-Day
124.24%
HV Rank
97.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($13.11 target)
2
Strong Buy8
Buy1
HoldLatest News
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
Zacks Investment Research6/25/2026Positive
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research6/25/2026Positive
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
GlobeNewsWire6/24/2026Neutral
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts
GlobeNewsWire6/24/2026Neutral
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha6/10/2026Neutral
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha6/5/2026Neutral
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:
GlobeNewsWire5/20/2026Neutral
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.
Zacks Investment Research5/8/2026Negative
More HEALTHCARE Stocks
Data last updated: 7/9/2026